
    
      This is an open-label, randomized, crossover, Phase I study intended to demonstrate the BE,
      and safety and tolerability profile of 2 formulations of BDM HCl administered to cancer
      patients: Eagle-BDM and Teva-BDM Histologically confirmed diagnosis of any malignant disease
      (solid tumors and hematologic malignancies are eligible) for which no curative or standard
      therapy is appropriate.

      At the end of the study, patients may be enrolled into an open-label extension (OLE) study
      (Study EGL-BDM-C-1301-OLE), at the discretion of the investigator.
    
  